Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Capvaxive be used to prevent invasive disease ...

(RTTNews) - Merck & Co Inc. (MRK), Thursday said it has decided to stop the Phase 3 HYPERION study evaluating Winrevair in pulmonary arterial hypertension (PAH). The HYPERION study is designed to ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...

Paula Annunziato, senior vice president, infectious diseases and vaccines, Global Clinical Development, Merck Research Laboratories, said, "Invasive pneumococcal disease can lead to serious ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of waveLINE-010, a pivotal ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Speaking on today's call will be Rob Davis, chairman and chief executive officer; Caroline Litchfield, chief financial officer; and Dr. Dean Li, president of Merck Research Labs. Before we get ...